✦ LIBER ✦

30. Open-label Phase I/II clinical trial of pyrimethamine for the treatment of chronic GM2 gangliosidosis

✍ Scribed by Joe Clarke; Edwin Kolodny; Don Mahuran; Maria Fuller; Michael Tropak; Jack Keimel; Swati Sathe; Sophia Pesotchinsky; Brigette Rigat

Book ID: 116988767
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 43 KB
Volume: 99
Category: Article
ISSN: 1096-7192
DOI: 10.1016/j.ymgme.2009.10.047

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An open-label Phase I/II clinical trial

An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay–Sachs or Sandhoff variants)

✍ Joe T.R. Clarke; Don J. Mahuran; Swati Sathe; Edwin H. Kolodny; Brigitte A. Riga 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 340 KB

An open-label phase I/II clinical trial

An open-label phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 Gangliosidosis (Tay-Sachs or Sandhoff variants)

✍ Joe Clarke; Don Mahuran; Swati Sathe; Edwin Kolodny; Brigitte Rigat; Julian Raim 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 56 KB

P.2.089 An open-label, Japanese, phase I

P.2.089 An open-label, Japanese, phase II clinical trial of ziprasidone in the treatment of schizophrenia

✍ M. Murasaki 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 152 KB

1411 CF102 FOR THE TREATMENT OF HEPATOCE

1411 CF102 FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA: A PHASE I/II, OPEN-LABEL, DOSE-ESCALATION STUDY

✍ Stemmer, S.M.; Benjaminov, O.; Medalia, G.; Ciuraru, N.B.; Silverman, M.H.; Bar- 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 62 KB

Efficacy of transdermal nitroglycerin co

Efficacy of transdermal nitroglycerin combined with etodolac for the treatment of chronic post-thoracotomy pain: An open-label prospective clinical trial

✍ Lucio Glantz; Galina Godovic; Margarita Lekar; Mordechai Kramer; Leonid A Eidelm 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 127 KB

Rituximab Plus Chlorambucil As First-Lin

Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study

✍ Hillmen, P.; Gribben, J. G.; Follows, G. A.; Milligan, D.; Sayala, H. A.; Moreto 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 141 KB